ALNY — Alnylam Pharmaceuticals Inc · P/E 76, rev $1.29B

Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.

Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.

Use this ALNY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALNY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALNY SEC filings page. Lician reads the product cache first so this HTML stays unique to Alnylam Pharmaceuticals Inc even when a live quote feed is slow.

Alnylam Pharmaceuticals Inc latest statements (FY2025)

Latest cached year on this hub. Full ALNY income, balance, and cash tables.

  • Revenue$3.71B
  • Net Income$313.7M
  • Total Assets$4.97B
  • Total Debt$0
  • Free Cash Flow$465.4M

ALNY recent filings